Total Payments
$728,183
2024 Payments
$202,586
Companies
60
Transactions
971
Medicare Patients
13,705
Medicare Billing
$3.0M
Payment Breakdown by Category
Other$486,872 (66.9%)
Consulting$152,696 (21.0%)
Travel$66,447 (9.1%)
Food & Beverage$20,701 (2.8%)
Education$1,137 (0.2%)
Research$330.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $463,022 | 192 | 63.6% |
| Consulting Fee | $152,696 | 70 | 21.0% |
| Travel and Lodging | $66,447 | 162 | 9.1% |
| Honoraria | $22,170 | 16 | 3.0% |
| Food and Beverage | $20,701 | 507 | 2.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,680 | 2 | 0.2% |
| Education | $1,137 | 21 | 0.2% |
| Unspecified | $330.00 | 1 | 0.0% |
Payments by Type
General
$727,853
970 transactions
Research
$330.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $206,839 | 168 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $127,252 | 103 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $68,437 | 50 | $0 (2024) |
| PharmaEssentia USA Corporation | $50,423 | 48 | $0 (2024) |
| Adaptive Biotechnologies Corporation | $32,449 | 29 | $0 (2024) |
| Astellas Pharma US Inc | $26,784 | 51 | $0 (2024) |
| GlaxoSmithKline, LLC. | $26,127 | 29 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $23,562 | 32 | $0 (2024) |
| Blueprint Medicines Corporation | $21,011 | 31 | $0 (2024) |
| ABBVIE INC. | $18,423 | 28 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $202,586 | 234 | GENZYME CORPORATION ($75,036) |
| 2023 | $206,621 | 289 | GENZYME CORPORATION ($52,333) |
| 2022 | $144,636 | 169 | GENZYME CORPORATION ($45,265) |
| 2021 | $95,592 | 124 | AstraZeneca Pharmaceuticals LP ($34,098) |
| 2020 | $55,394 | 66 | AstraZeneca Pharmaceuticals LP ($24,049) |
| 2019 | $15,180 | 44 | Astellas Pharma US Inc ($12,799) |
| 2018 | $6,994 | 18 | Bayer HealthCare Pharmaceuticals Inc. ($4,380) |
| 2017 | $1,179 | 27 | Amgen Inc. ($501.23) |
All Payment Transactions
971 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $2,016.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/19/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | Cash or cash equivalent | $74.52 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/18/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/18/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.66 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | In-kind items and services | $593.88 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,325.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $21.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | Cash or cash equivalent | $7.05 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,008.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $504.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/02/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $127.54 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/25/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $475.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,618.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $1,840.65 | General |
| Category: Oncology | ||||||
| 11/21/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $112.20 | General |
| Category: Oncology | ||||||
| 11/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,873.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $107.35 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,618.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $2,612.50 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $455.60 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $409.95 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $43.75 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | Cash or cash equivalent | $12.20 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $43.03 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PF06647263 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 3,345 | 47,188 | $2.5M | $567,713 |
| 2022 | 65 | 3,575 | 71,760 | $3.4M | $672,928 |
| 2021 | 59 | 3,540 | 69,122 | $3.4M | $786,518 |
| 2020 | 60 | 3,245 | 47,342 | $3.8M | $964,582 |
Total Patients
13,705
Total Services
235,412
Medicare Billing
$3.0M
Procedure Codes
234
All Medicare Procedures & Services
234 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 28 | 7,400 | $1.0M | $320,000 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 170 | 471 | $173,328 | $44,117 | 25.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 13 | 14,980 | $299,600 | $35,581 | 11.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 141 | $69,936 | $19,321 | 27.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 137 | 164 | $115,948 | $17,187 | 14.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 11 | 14 | $67,228 | $15,436 | 23.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 156 | 246 | $61,500 | $14,891 | 24.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 300 | 964 | $61,696 | $9,912 | 16.1% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 81 | 522 | $31,320 | $8,688 | 27.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 50 | 50 | $35,450 | $8,416 | 23.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 85 | $30,345 | $7,959 | 26.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 264 | 916 | $18,320 | $7,694 | 42.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 280 | 890 | $32,040 | $6,723 | 21.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 30 | 31 | $33,077 | $5,690 | 17.2% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 301 | 939 | $29,109 | $5,521 | 19.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 92 | 201 | $31,557 | $4,561 | 14.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 117 | 267 | $16,020 | $3,567 | 22.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 30 | 53 | $13,091 | $3,299 | 25.2% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 36 | 91 | $13,013 | $3,188 | 24.5% |
| 83550 | Iron binding capacity | Office | 2023 | 116 | 265 | $9,275 | $2,271 | 24.5% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 37 | 38 | $31,198 | $2,190 | 7.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 33 | 41 | $14,104 | $2,114 | 15.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 91 | 151 | $16,308 | $1,848 | 11.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 40 | 169 | $16,224 | $1,826 | 11.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 18 | 20 | $13,140 | $1,726 | 13.1% |
About Dr. Edward Pearson, MD
Dr. Edward Pearson, MD is a Internal Medicine healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2011. The National Provider Identifier (NPI) number assigned to this provider is 1801188172.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Pearson, MD has received a total of $728,183 in payments from pharmaceutical and medical device companies, with $202,586 received in 2024. These payments were reported across 971 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($463,022).
As a Medicare-enrolled provider, Pearson has provided services to 13,705 Medicare beneficiaries, totaling 235,412 services with total Medicare billing of $3.0M. Data is available for 4 years (2020–2023), covering 234 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Student in an Organized Health Care Education/Training Program, Hematology & Oncology
- Location Dallas, TX
- Active Since 05/05/2011
- Last Updated 08/03/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1801188172
Products in Payments
- SARCLISA (Biological) $197,843
- CALQUENCE (Drug) $127,038
- BESREMI (Drug) $50,423
- clonoSEQ (Device) $32,316
- OJJAARA (Drug) $26,068
- XOSPATA (Drug) $25,258
- REBLOZYL (Biological) $23,480
- Rezlidhia (Drug) $23,454
- ONUREG (Drug) $23,314
- Pomalyst (Drug) $22,649
- JAKAFI (Drug) $17,739
- Epkinly (Drug) $17,049
- TIBSOVO (Drug) $15,284
- AYVAKIT (Drug) $14,733
- VENCLEXTA (Drug) $12,018
- EPKINLY (Drug) $6,404
- Tibsovo (Drug) $5,919
- JAYPIRCA (Drug) $3,663
- IMBRUVICA (Drug) $2,679
- SCEMBLIX (Drug) $2,619
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Dallas
Andrew Whiteley
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Biff Palmer, Md, MD
Internal Medicine — Payments: $980,569
Internal Medicine $980,569
Dr. Robert Gottlieb, M.d. Ph.d, M.D. PH.D
Internal Medicine — Payments: $832,284
Internal Medicine $832,284
Dr. Ronan Kelly, Md, MD
Internal Medicine — Payments: $813,092
Internal Medicine $813,092
Dr. Gates Colbert, M.d, M.D
Internal Medicine — Payments: $801,349
Internal Medicine $801,349
Dr. Zoran Kurepa, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $743,379
Internal Medicine $743,379